RxDoctor Payments Data

Ivan Cerezo, MD

Cardiovascular Disease · Dorado, PRNPI 1578607776

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,832 of the $9,287 with a category attached, or 62.8%. 14 manufacturers reported payments, led by Medtronic at 39.8% of the total. Reporting peaked in 2024 at $3,083 and has fallen 78.1% since, to $675 in 2025.

$9,287in general payments, 2019–2025

Across 210 payments — averaging $44.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Johnson & Johnson$2K
  • AstraZeneca$741
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$699
  • E.r. Squibb & Sons, L.L.C.$616
  • Boston Scientific$437
  • plus $901 from 8 others

What the payments were for

  • Consulting fees$1,35015%
  • Travel & lodging$2,09123%
  • Food & beverage$5,83263%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)28$3,692
Johnson & Johnson45$2,202
AstraZeneca27$741
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)34$699
E.r. Squibb & Sons, L.L.C.23$616
Boston Scientific15$437
PBG Puerto Rico LLC18$349
Abbott5$200
Amgen7$166
Boehringer Ingelheim3$84
Merck2$40
Biotronik Inc.1$24
Chiesi USA, Inc.1$22
Pfizer Pharmaceuticals LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,287 in reported general payments places this provider in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$19,507
Medicare patients
86
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$353,357
XareltoRivaroxaban229$256,567
EntrestoSacubitril/Valsartan75$111,195
JardianceEmpagliflozin58$54,606
FarxigaDapagliflozin Propanediol39$39,869
Repatha SureclickEvolocumab34$34,728
Repatha PushtronexEvolocumab24$20,749
BrilintaTicagrelor15$13,807
Candesartan Cilexetil85$11,857
Metoprolol Succinate560$11,096
Atorvastatin Calcium592$8,564
Rosuvastatin Calcium433$7,711
Irbesartan206$7,115
Losartan Potassium522$6,890
Janumet XrSitagliptin Phos/Metformin Hcl11$5,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$2,202$256,567229 claims
Boehringer IngelheimJardiance$84$54,60658 claims
AstraZenecaFarxiga, Brilinta$741$53,67654 claims
MerckJanumet Xr$40$5,96011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Dorado

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →